title: Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?
authors.affiliation: Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, NJ 07109-0023, Belleville, USA. dmg.gscancer@att.net
authors.forename: David M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: Chien-Hsing
authors.initials: CH
authors.lastname: Chang
authors.forename: Robert M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: Edmund A
authors.initials: EA
authors.lastname: Rossi
authors.forename: Habibe
authors.initials: H
authors.lastname: Karacay
authors.forename: William
authors.initials: W
authors.lastname: McBride
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Chatal
authors.forename: Jacques
authors.initials: J
authors.lastname: Barbet
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001360:Avidin / Q000627:therapeutic use*; D001710:Biotin / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011878:Radiotherapy / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D001360:Avidin; D001710:Biotin